US-listed company Vida Global will pay its global team in bitcoin, with settlements in US dollars.
Foresight News reported, citing FinanceWire, that NYSE American-listed company Vida Global (NYSE American: VIDA) has announced the adoption of Voltage Credit to pay its global team members in Bitcoin via the Lightning Network, while all company accounting is fully settled in US dollars. Under this mechanism, Vida uses a revolving credit line to instantly issue Bitcoin salaries and settles the outstanding balance in US dollars at the end of each month, in the same manner as standard vendor invoices, thereby eliminating the need to hold a Bitcoin wallet or reflect cryptocurrency on the balance sheet.
Lyle Pratt, founder and CEO of Vida, stated: "Vida has a global team, including members in Argentina, who prefer to be paid in Bitcoin due to the many challenges facing the local currency."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure
According to media reports citing sources familiar with the matter, SpaceX is preparing to complete a debt issuance totaling $40 billion, with an interest rate significantly higher than previous borrowing costs, reflecting growing investor concerns over financing for artificial intelligence (AI) infrastructure.
Tom Lee: The market is in a sell-off state, and tech stocks have reached support levels
TS Lombard scenario analysis: An AI bubble burst could trigger a 30% plunge in the S&P 500, wiping out 20 trillion dollars in market value—but don't rush to short!
Dario Perkins from TS Lombard predicted in a scenario analysis released on Thursday that if AI capital expenditure collapses, approximately $20 trillions in U.S. stock market value could evaporate, triggering credit losses of $125 billions to $190 billions.
Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline
Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.
Crypto prices
More
